Proactive Investors - Run By Investors For Investors

Wynnstay Properties and more...

Wynnstay Properties and more...

Small Cap Breakfast                           

Set menu

AIM:

 

Total number of AIM Companies (Incl Susp):

 

937*

 

Total number of AIM Companies trading:

 

867*

 

*as at close of business  23 July 2018

 

Standard List**  of Main Market:

 

Total number of Standard List Companies

(Incl Susp):

137*

Total number of Standard List Companies trading:

124*

*as at close of business 23 July 2018

 

NEX Growth Market:

 

Total number of NEX Growth Market Companies (Incl Susp):

 

87*

 

Total number of NEX Growth Market Companies trading:

 

84*               

 

*as at close of business  23 July 2018

             

*A corporate client of Hybridan LLP

 

**  Standard Listing as defined by Hybridan LLP to be a business with strictly operational activity

                     

Dish of the day

 

No Joiner Today

 

Off the menu  

 

Alpha Pyrenees Trust has left the Offficial List (Standard)

     

What’s cooking in the IPO kitchen?

 

NEX Exchange Growth Market

 

Veni Vidi Vici. Investment Vehicle to identify investment opportunities and acquisitions in companies in the Precious Metals and Base Metals sectors.  Raising £490k at 50p. Market cap £0.8m. Due 8 August.

 

AIM

 

Jadestone Energy (JSE.TO)—an independent oil and gas production and development company focused on the Asia-Pacific region. Pro-forma production of 13.9 mboe/d, 2P reserves of 45.3 MMboe, and a 2P NPV10 of US$563.7 million .  Offer TBA. Current mkt cap C$135m. Due early August.

 

CentralNic-Schedule 1 from the business operating in proprietary retail platforms selling domain names and associated web presence services including hosting and email on a subscription basis, has acquired KeyDrive S.A  which constitutes a RTO. Raising  £24m at 52p, combined market cap of £88.7m

 

Trackwise—established business that manufactures specialist products using printed circuit technology. Offer TBA. Due Late July

 

Ovoca Gold (to be renamed Ovoca Bio PLC) - RTO of IVIX, a Russian company developing a drug candidate for the treatment of female sexual dysfunctions. No monies to be raised, market cap of £8.5m, due 30 July

 

Nucleus Financial—independent wrap platform provider . FYDec17 revs £40.36m and PBT of £5.1m. Offer TBA. Due late July.

 

Kropz PLC-Intention to float by the  emerging plant nutrient producer with an advanced stage phosphate mining project in South Africa and exploration assets in West Africa

 

Main Market (Premium)

 

Grit Real Estate Income Group pan-African income real estate company focused on real estate investment assets in pre-selected African countries . Looking to raise net proceeds of at least $120m. To be priced at EPRA NAV of $1.43/share.  Due 31 July.

                               

Breakfast Buffet

 

Eagle Eye Solutions (LON:EYE) 150p £43.3m

 

 FYJun18 update from the  SaaS technology company that enables businesses to create a real-time connection with their customers.

 

·      Group revenue increased 33% to £14.8m (FY17: £11.1m)

 

·      Recurring revenue increased to c. 77% of Group revenue (FY17: 68%) and grew by 51% from the prior year

 

·      Adjusted EBITDA** loss of £(2.0)m (FY17: £(1.8)m)

 

·      Total volumes through the platform increased 556% to 403.7m (FY17: 61.5m)

 

·      Successful launch of Canada's leading loyalty programme with Loblaw, illustrating the Group's international reach and scalability

 

·      Significant blue-chip client and partner wins including Boparan, M&Co, Greene King, Groupon and Google

 

James Halstead (LON:JHD) 395p £828m

 

FYJun18 update from the commercial flooring manufacturer and distributor. “Sales for the year were ahead of the comparative year. This represents a creditable performance in still difficult trading conditions. It is particularly pleasing to report that our UK turnover is 3% ahead of the prior year in a market that seems to be quite robust despite the well reported spending cuts and high street retailer issues.

 

In the Chairman's interim statement, announced on 29 March 2018, it was noted that adverse price pressure on raw materials was holding back the benefits of export currency gains. This continued in the second half year but was ameliorated by increased sales.” “we are pleased to anticipate, once again, reporting record turnover and expect profits for the year to 30 June 2018 will be in line with last year.” FY18E rev £248m and EBITDA £52m.

 

Wynnstay Properties (LON:WSP) 565p £15.32m

 

 “The Company is pleased to announce that it has exchanged contracts for the acquisition of a freehold multi-let trade counter estate comprising Units 10-15 Petersfield Business Park, Petersfield from Friars House Investments Limited for £3.83 million. The total acquisition cost of £4.1 million, which includes stamp duty and other acquisition costs, will be funded from existing cash resources and debt facilities.  The estate is fully let and produces a current rent of £203,592 per annum.” "We are pleased to have secured the Petersfield property for the Wynnstay portfolio in a keen bidding process.  It provides a good fit with our other assets in Hampshire, Surrey and Sussex, in terms of size, lease profile and tenant mix.  We hope that there may be possible opportunities to build on our presence in Petersfield in due course although this will take time and effort in the current market conditions."

 

Empresaria (LON:EMR) 80p £36.5m

 

“HY update from the international specialist staffing group. Empresaria remains on course to meet market expectations for the full year. For the first half, adjusted profit before tax is up approximately 2% and net fee income is down approximately 1% on the prior year. There were strong results in a number of businesses, particularly within the Americas region, offsetting the previously announced impact of regulatory changes in Germany and Japan. The Group's strategy of specialisation and diversification continues to lay the foundations for future profitable growth.” Recent investment in Grupo Solimano in Peru strengthens the Group's presence in Latin America. To be funded by the operating cash flows of the Group and is expected to earnings enhancing in the next financial year. PE <6x, yield c.2%

 

Gfinity (LON:GFIN) 13.1p £37.5m

 

 The “esports solutions provider, today announces a multi-season agreement with Domino's to become Presenting Partner of the Gfinity Challenger and Elite Series UK. The significant investment into the Gfinity Challenger and Elite Series UK enables Domino's to connect and engage within one of the fastest-growing entertainment sectors and target the young adult demographic that consumes gaming and esports content daily via digital platforms.

 

The partnership, which runs until December 2020, represents the biggest commercial deal in the Company's history and is further evidence of the world's leading brands being attracted to both esports and Gfinity, with previous partners including Unilever (Lynx), HP Omen and Turtle Beach.”

 

Van Elle (LON:VANL) 82p £66.85m

 

FYApr18 results from the  geotechnical contractor offering a wide range of ground engineering techniques and services to customers in a variety of UK construction end markets.

 

Group revenue increased by 10.4% to £103.9m driven by activity in new housing and infrastructure sectors

 

Underlying operating profit was down 4% to £11.1m reflecting contract specific issues in the rail and ground stabilisation units together with challenging market conditions in H2

 

Completed major new rig investment programme with fleet increasing from 111 to 123 rigs

 

·      Strong balance sheet with net debt at 30 April 2018 of £5.9m, 0.4x EBITDA

 

CEO succession process complete, with Mark Cutler to start in August 2018  The Board is recommending a final dividend of 2.3p per share (total dividend of 3.7p per share.  PE c.8x and yield 4.5%

 

APC Technology (LON:APC) 7p £9.4m

 

The provider of design-in, specification and distribution services for specialist electronic components and systems, lighting technologies and connectivity products, is announced the acquisition of Aspen Electronics Limited and a placing, including the sale of Vendor Ordinary Sharesat 6.75 pence per Ordinary Share, to raise approximately £2.54 million before expenses.  Consideration of £2.2m in cash and shares.

 

Aspen is a premium distributor of electronic components, specialising in radio frequency (RF) and microwave components and test and measurement equipment. - Complementary RF and microwave business to APC's which the Board expects will lead to top line synergy opportunities. Expected to be earnings enhancing in the first full year after Completion. Aspen FYJun17 rev £4.3m and adjusted EBITDA of £0.35m.

 

FYAug18E rev £17.5m and PBT £0.7m.

 

Tern PLC (LON:TERN) 32.75p £64.8m

 

 The “the investment company specialising in the Internet of Things ("IoT"), is pleased to announce that it has raised approximat­ely £2.9 million before expenses through an unconditional placing of 11,192,307 new ordinary shares of 0.02p each at a price of 26 pence per ordinary share [a  20% discount to yesterday’s close] (the "Placing"), utilising the existing share authorities granted at the 2018 AGM.

 

The funds raised will place Tern in a stronger financial position for upcoming investment negotiationsand will also provide additional finance to develop the businesses of the existing portfolio companies.”

 

Evgen (LON:EVG)17.75p £16.57m

 

 The ‘clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that it has concluded patient recruitment in its STEM Phase IIa trial of SFX-01 in metastatic breast cancer. STEM is an open label trial that had regulatory approval to recruit 60 patients. Following the favourable interim read-out, announced on 11 June 2018, the Principal Investigator and the Company's medical adviser believe there is sufficient evidence to conclude that the main aims of the trial, being a favourable safety and tolerability profile and evidence of clinical benefit, have been successfully met. On this basis, the Company has decided that there is no merit in recruiting the full number of patients allowed under the protocol.’ Final read out  due around the end of the year.  “The next step is likely to be a placebo-controlled trial, testing SFX-01 in combination with second-line hormone therapy in patients that have failed on CDK4/6 inhibitors.”  

 

Norcros (LON:NXR) 216p £174m

 

 AGM statement from the market leading supplier of high quality and innovative bathroom and kitchen products. “The Group's overall trading for the first quarter was in line with the Board's expectations.

 

Group revenue for the 13 week period was 15.5% higher on a reported basis compared to the same period last year.

 

On a like-for-like basis Group revenue was 0.9% higher than the previous year. This performance reflected strong revenue growth of 6.9% in the Group excluding Johnson Tiles and the expected revenue reduction at Johnson Tiles which was largely due to the Kingfisher unified programme as previously reported on in the Group's 2018 results.”

 

“We experienced further progress in our South African business which grew revenue by 8.5% in Sterling terms and 8.9% at constant currency.” PE c.7x and yield c.4%. 

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute “independent investment research” for the purposes of the Financial Conduct Authority rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the Financial Conduct Authority) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the Financial Conduct Authority).

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use